A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.

NCT Number	NCT07613216
Lead Sponsor	Cosmos Rx, Inc Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Sentara Norfolk General Hospital
Conditions	Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Enrollment	100 participants
Start Date	2026-07
Primary Completion	2027-07 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-29